Preclinical pharmacology, toxicology, biodistribution and dosimetry, and radionuclide production CMC validation for PB-212 receptor targeted alpha-particle therapy for neuroendocrine tumors

Ended Project Grant Awarded Last action

Award ID
R44CA250872
Recipient
Awarding agency
Obligated
$1,996,306

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date
Place of performance
Iowa, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $998,648
Amendment $0
Original award $997,658

Quick answers

Who received award R44CA250872?

R44CA250872 was awarded to Viewpoint Molecular Targeting, Inc. by National Cancer Institute (National Institutes of Health) on September 15, 2020.

How much is award R44CA250872 worth?

$1,996,306 has been obligated on R44CA250872.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award